1. Home
  2. BLDR vs KOD Comparison

BLDR vs KOD Comparison

Compare BLDR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Builders FirstSource Inc.

BLDR

Builders FirstSource Inc.

HOLD

Current Price

$56.84

Market Cap

5.7B

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$86.87

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLDR
KOD
Founded
1998
2009
Country
United States
United States
Employees
N/A
N/A
Industry
RETAIL: Building Materials
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
5.5B
IPO Year
2005
2018

Fundamental Metrics

Financial Performance
Metric
BLDR
KOD
Price
$56.84
$86.87
Analyst Decision
Buy
Strong Buy
Analyst Count
24
7
Target Price
$71.36
★ $121.67
AVG Volume (30 Days)
2.2M
★ 3.2M
Earning Date
10-29-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $15,190,638,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.18
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$49.67
$15.83
52 Week High
$131.50
$104.00

Technical Indicators

Market Signals
Indicator
BLDR
KOD
Relative Strength Index (RSI) 51.20 59.00
Support Level $56.56 $79.06
Resistance Level $61.82 $103.63
Average True Range (ATR) 2.12 6.44
MACD 0.78 -2.33
Stochastic Oscillator 90.94 33.91

Price Performance

Historical Comparison
BLDR
KOD

About BLDR Builders FirstSource Inc.

Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: